This article was originally published in The Tan Sheet
Procter & Gamble estimates first quarter earnings of $.72 per share, an increase of 14% versus the prior-year quarter, company announces during the Prudential Back to School Consumer Conference Sept. 9. The marketer of Crest oral care products also expects organic sales growth in Q1 to be in the 4% to 6% range, excluding the estimated impacts of acquisitions and divestitures as well as foreign exchange. The estimates are based in part on "robust" first-quarter initiatives, the firm notes...
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Formycon and partner Bioeq have offered further details on timing for the submission of their FYB201 proposed ranibizumab biosimilar version of Lucentis in Europe, the US and elsewhere.
The fresh cash injection will fund Phase II studies evaluating the UK firm's 12-month treatment for diabetic macular edema.